Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2001, p. 1952-1954, Vol. 45, No. 7
Division of Pediatric Infectious Diseases,
Alfred I. duPont Hospital for Children,
Wilmington,1 and Infectious Diseases
Laboratory, Christiana Hospital, Christiana Care Health System,
Newark,2 Delaware
Received 17 August 2000/Returned for modification 1 February
2001/Accepted 30 March 2001
The in vitro activities of meropenem, linezolid,
quinupristin-dalfopristin, vancomycin, and penicillin against 130 clinical isolates of group C and G streptococci, including
vancomycin-tolerant isolates, were evaluated. Meropenem, linezolid,
quinupristin-dalfopristin, vancomycin, and penicillin MICs at which
90% of the isolates were inhibited were 0.06, 2.0, 0.25, 0.5, and
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.1952-1954.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
In Vitro Activities of Linezolid, Meropenem, and
Quinupristin-Dalfopristin against Group C and G Streptococci,
Including Vancomycin-Tolerant Isolates
0.016 µg/ml, respectively. Meropenem, linezolid,
quinupristin-dalfopristin, and penicillin were active against group C
and G streptococci, including vancomycin-resistant strains.
*
Corresponding author. Mailing address: Division of
Pediatric Infectious Diseases, Alfred I. duPont Hospital for Children, P.O. Box 269, Wilmington, DE 19899. Phone: (302) 651-4421. Fax: (302)
651-4463. E-mail: jklein{at}nemours.org.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»